Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study.

Saved in:
Bibliographic Details
Title: Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study.
Authors: Rugo HS; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. Hope.Rugo@ucsf.edu., Kabos P; Divisions of Medical Oncology, Department of Medicine, University of Colorado, Anschutz Medical Campus, 12801 East 17th Avenue, Aurora, CO, 80045, USA., Beck JT; Highlands Oncology Group, Fayetteville, AR, USA., Jerusalem G; Laboratory of Medical Oncology, University of Liège, Liège, Belgium.; Department of Medical Oncology, CHU Sart-Tilman Liège, Liège, Belgium., Wildiers H; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium., Sevillano E; Department of Medical Oncology, Centro Integral Oncologico Clara Campal, Madrid, Spain., Paz-Ares L; Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain., Chisamore MJ; Department of Clinical Research, Merck & Co., Inc., Rahway, NJ, USA., Chapman SC; Eli Lilly and Company, Bracknell, UK., Hossain AM; Eli Lilly and Company, Indianapolis, IN, USA., Chen Y; Eli Lilly and Company, Indianapolis, IN, USA., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Source: NPJ breast cancer [NPJ Breast Cancer] 2022 Nov 05; Vol. 8 (1), pp. 118. Date of Electronic Publication: 2022 Nov 05.
Publication Type: Journal Article
Journal Info: Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2374-4677
DOI:10.1038/s41523-022-00482-2